Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: Effect on mitochondrial function

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 3, 2014, Pages 274-281

  Messadi, Erij ^a,c,d   Aloui, Zohra ^d,e   Belaidi, Elise ^c   Vincent, Marie Pascale ^a   Couture Lepetit, Elisabeth ^c   Waeckel, Ludovic ^a   Decorps, Johanna ^c   Bouby, Nadine ^a   Gasmi, Ammar ^b,d,e   Karoui, Habib ^d,e   Ovize, Michel ^c   Alhenc Gelas, François ^a   Richer, Christine ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^d UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^e CarMeN   (France)

Author keywords

Cardiac ischemia reperfusion; Mitochondria; Myocardial infarction; VEGF

Indexed keywords

CALCIUM ION; CARDIOVASCULAR AGENT; INCREASING CAPILLARY PERMEABILITY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2 ANTAGONIST; VIPER VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IN VIVO STUDY; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VIPER VENOMS;

EID: 84896318095     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000045     Document Type: Article

References (54)

1. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112:2143-2148
2. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359: 473-481
3. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332-2336
4. Lefer AM, Tsao PS, Lefer DJ, et al. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 1991;5:2029-2034
5. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858
6. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitaryderived folliculo stellate cells. Proc Natl Acad Sci USA. 1989;86: 7311-7315
7. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028
8. Shyu KG, Chang H, Wang BW, et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med. 2003;114:85-92
9. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662-670
10. Zimmerman MA, Selzman CH, Raeburn CD, et al. Clinical applications of cardiovascular angiogenesis. J Card Surg. 2001;16:490-497
11. Gupta K, Kshirsagar S, Li W, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247:495-504
12. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol. 1993;264:C995-C1002
13. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581
14. Hashimoto E, Ogita T, Nakaoka T, et al. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol. 1994;267:H1948-H1954
15. Infanger M, Faramarzi S, Grosse J, et al. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/ reperfusion injury. Cardiovasc Pathol. 2007;16:291-299
16. Addya S, Shiroto K, Turoczi T, et al. Ischemic preconditioning-mediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice. J Mol Cell Cardiol. 2005;38:345-351
17. Guzman MJ, Crisostomo PR, Wang M, et al. Vascular endothelial growth factor improves myocardial functional recovery following ischemia/ reperfusion injury. J Surg Res. 2008;150:286-292
18. Kaga S, Zhan L, Altaf E, et al. Glycogen synthase kinase-3beta/ betacatenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol. 2006;40:138-147
19. Kupatt C, Hinkel R, Vachenauer R, et al. VEGF165 transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: Role of eNOS phosphorylation. FASEB J. 2003;17:705-707
20. Luo Z, Diaco M, Murohara T, et al. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann Thorac Surg. 1997;64:993-998
21. Meng X, Brown JM, Ao L, et al. Reduction of infarct size in the rat heart by LPS preconditioning is associated with expression of angiogenic growth factors and increased capillary density. Shock. 1999;12:25-31
22. Thirunavukkarasu M, Juhasz B, Zhan L, et al. VEGFR1 (Flt-1+/-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic Biol Med. 2007;42:1487-1495
23. Ku DD, Zaleski JK, Liu S, et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265:H586-H592
24. Van Der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997; 95:1030-1037
25. Asahara T, Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation. 1996;94:3291-3302
26. Molin D, Post MJ. Therapeutic angiogenesis in the heart: Protect and serve. Curr Opin Pharmacol. 2007;7:158-163
27. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142
28. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69:165-175
29. Smith EF III, Gallenkamper W, Beckmann R, et al. Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): Effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res. 1984;18:163-173
30. Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005;111:194-197
31. Bernardi P, Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: A critical appraisal. J Bioenerg Biomembr. 1996;28:131-138
32. Crompton M, Costi A. A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J. 1990;266:33-39
33. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995;307(pt 1):93-98
34. Wright GL, Maroulakou IG, Eldridge J, et al, Muise- Helmericks RC. VEGF stimulation of mitochondrial biogenesis: Requirement of AKT3 kinase. FASEB J. 2008;22:3264-3275
35. Gasmi A, Bourcier C, Aloui Z, et al. Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. J Biol Chem. 2002;277:29992-29998
36. Gasmi A, Abidi F, Srairi N, et al. Purification and characterization of a growth factor-like which increases capillary permeability from Vipera lebetina venom. Biochem Biophys Res Commun. 2000;268:69-72
37. Cebulla CM, Jockovich ME, Boutrid H, et al. Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma. Open Ophthalmol J. 2008;2: 62-67
38. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Immunol. 2002;168:3595-3600
39. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 2005;19: 1172-1174
40. Argaud L, Gateau-Roesch O, Chalabreysse L, et al. Preconditioning delays Ca2+-induced mitochondrial permeability transition. Cardiovasc Res. 2004;61:115-122
41. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254
42. Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev. 1999;79:1127-1155
43. Gomez L, Chavanis N, Argaud L, et al. Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2005;289:H2153-H2158
44. Gomez L, Raisky O, Chalabreysse L, et al. Link between immune cell infiltration and mitochondria-induced cardiomyocyte death during acute cardiac graft rejection. Am J Transplant. 2006;6:487-495
45. Ichas F, Jouaville LS, Sidash SS, et al. Mitochondrial calcium spiking: A transduction mechanism based on calcium-induced permeability transition involved in cell calcium signalling. FEBS Lett. 1994;348:211-215
46. Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol Relat Subj Biochem. 1956;17:65-134
47. Aloui Z, Hoos S, Geretti E, et al. Novel svVEGF isoforms from Macrovipera lebetina venom interact with neuropilins. Biochem Biophys Res Commun. 2009;389:10-15
48. Boguslawski G, McGlynn PW, Harvey KA, et al. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2004;279:5716-5724
49. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107
50. Messadi-Laribi E, Griol-Charhbili V, Pizard A, et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther. 2007;323:210-216
51. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: Two sides of the same coin. Antioxid Redox Signal. 2011;14:893-907
52. Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549
53. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: From investigative tool to therapeutic agent. Br J Pharmacol. 2012;165:1235-1245
54. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res. 2004;61:372-385